Natera’s Fetal Focus NIPT Trial Enrolls Over 2,000 Patients
Natera, Inc. has announced significant progress in its EXPAND clinical trial, which is focused on studying its Fetal Focus single-gene noninvasive prenatal test (NIPT). The trial has surpassed 2,000 patient enrollments, marking a doubling in participation over the past year. The trial aims to provide insights into the effectiveness of this prenatal testing method and was recently highlighted during a plenary session at a maternal-fetal medicine conference.
AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months. EXPAND is a prospective, blinded, multi-site clinical trial designed to study Natera’s Fetal Focus single-gene noninvasive prenatal test (NIPT). The trial was featured in an oral plenary session at the Society for Maternal-Fetal Me